- Though antiviral treatments can suppress Hepatitis C virus (HCV) and Hepatitis B virus (HBV) viral load in chronic infection, novel strategies to enhance long term viral clearance and sustained immunological control represent a signifi cant unmet medical need. Most HBV patients require chronic suppressive antiviral treatment for an indefi nite period.
- GS-9620 is a potent oral TLR7 agonist being developed for the treatment of chronic Hepatitis B and C.
- The goal of GS-9620 treatment is to stimulate an innate antiviral response and enhance an antiviral adaptive immune response.
- Woodchucks chronically infected with woodchuck hepatitis virus (WHV), an animal model for chronic HBV, were treated with oral GS-9620 to investigate its efficacy. 作者: a46346310 时间: 2012-2-11 09:55